NCT03334786View on ClinicalTrials.gov

Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

April 5, 2018

Primary Completion Date

August 23, 2018

Study Completion Date

August 23, 2018

Conditions

Amyotrophic Lateral SclerosisFasciculation

Interventions

DRUG

FLX-787-ODT

Oral Disintegrating Tablet

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Lead Sponsor

Flex Pharma, Inc.

All Listed Sponsors

lead

Flex Pharma, Inc.

INDUSTRY